Cargando…
Concordance of human equilibrative nucleoside transporter‐1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial
BACKGROUND: Expression of human equilibrative nucleoside transporter‐1 (hENT1) is reported to predict survival of gemcitabine (GEM)‐treated patients. However, predictive values of immunohistochemical hENT1 expression may differ according to the antibodies, 10D7G2 and SP120. AIM: We aimed to investig...
Autores principales: | Okamura, Yukiyasu, Boku, Narikazu, Ghaneh, Paula, Greenhalf, William, Yasukawa, Satoru, Narimatsu, Hiroto, Fukutomi, Akira, Konishi, Masaru, Morinaga, Soichiro, Toyama, Hirochika, Maeda, Atsuyuki, Shimizu, Yasuhiro, Nakamori, Shoji, Sata, Naohiro, Yamakita, Keisuke, Takahashi, Amane, Takayama, Wataru, Yamaguchi, Ryuzo, Tomikawa, Moriaki, Yanagisawa, Akio, Neoptolemos, John P., Uesaka, Katsuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124504/ https://www.ncbi.nlm.nih.gov/pubmed/34327872 http://dx.doi.org/10.1002/cnr2.1507 |
Ejemplares similares
-
Human equilibrative nucleoside transporter‐1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S‐1 chemotherapy
por: Okamura, Yukiyasu, et al.
Publicado: (2019) -
JASPAC: Japan Spastic Paraplegia Research Consortium
por: Koh, Kishin, et al.
Publicado: (2018) -
Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05)
por: Takahashi, Shinichiro, et al.
Publicado: (2017) -
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016) -
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010)